User profiles for David Holtzman
 | David HoltzmanWashington University in St. Louis Verified email at neuro.wustl.edu Cited by 169017 |
Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease
Glia have been implicated in Alzheimer’s disease (AD) pathogenesis. Variants of the microglia
receptor triggering receptor expressed on myeloid cells 2 (TREM2) increase AD risk, and …
receptor triggering receptor expressed on myeloid cells 2 (TREM2) increase AD risk, and …
[PDF][PDF] The role of apolipoprotein E in Alzheimer's disease
The ɛ4 allele of apolipoprotein E (APOE) is the major genetic risk factor for Alzheimer's
disease (AD). Although there have been numerous studies attempting to elucidate the …
disease (AD). Although there have been numerous studies attempting to elucidate the …
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans
…, ST DeKosky, JC Morris, DM Holtzman - Annals of …, 2006 - Wiley Online Library
Objectives Amyloid‐β 42 (Aβ 42 ) appears central to Alzheimer's disease (AD) pathogenesis
and is a major component of amyloid plaques. Mean cerebrospinal fluid (CSF) Aβ 42 is …
and is a major component of amyloid plaques. Mean cerebrospinal fluid (CSF) Aβ 42 is …
Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy
…, RJ Perrin, M Farlow, JP Chhatwal, DM Holtzman… - Nature, 2021 - nature.com
Alzheimer’s disease (AD) is the most prevalent cause of dementia 1 . Although there is no
effective treatment for AD, passive immunotherapy with monoclonal antibodies against …
effective treatment for AD, passive immunotherapy with monoclonal antibodies against …
[PDF][PDF] The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases
Microglia play a pivotal role in the maintenance of brain homeostasis but lose homeostatic
function during neurodegenerative disorders. We identified a specific apolipoprotein E (APOE)…
function during neurodegenerative disorders. We identified a specific apolipoprotein E (APOE)…
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
…, JC Dodart, SM Paul, DM Holtzman - Proceedings of the …, 2001 - National Acad Sciences
Active immunization with the amyloid β (Aβ) peptide has been shown to decrease brain Aβ
deposition in transgenic mouse models of Alzheimer's disease and certain peripherally …
deposition in transgenic mouse models of Alzheimer's disease and certain peripherally …
Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease
DM Holtzman, KR Bales, T Tenkova… - Proceedings of the …, 2000 - National Acad Sciences
Apolipoprotein E (apoE) alleles determine the age-adjusted relative risk (ɛ4 > ɛ3) for
Alzheimer's disease (AD). ApoE may affect AD pathogenesis by promoting deposition of the …
Alzheimer's disease (AD). ApoE may affect AD pathogenesis by promoting deposition of the …
[HTML][HTML] NIA-AA research framework: toward a biological definition of Alzheimer's disease
…, B Dunn, SB Haeberlein, DM Holtzman… - Alzheimer's & …, 2018 - Elsevier
In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic
recommendations for the preclinical, mild cognitive impairment, and dementia stages of …
recommendations for the preclinical, mild cognitive impairment, and dementia stages of …
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on …
The National Institute on Aging and the Alzheimer’s Association charged a workgroup with
the task of developing criteria for the symptomatic predementia phase of Alzheimer’s disease (…
the task of developing criteria for the symptomatic predementia phase of Alzheimer’s disease (…
National Institute of Neurological Disorders and Stroke–Canadian stroke network vascular cognitive impairment harmonization standards
Background and Purpose— One in 3 individuals will experience a stroke, dementia or both.
Moreover, twice as many individuals will have cognitive impairment short of dementia as …
Moreover, twice as many individuals will have cognitive impairment short of dementia as …